Can a new spin on old technology outfox CAR-T?

Is anything too weighty to be explained over the internet? And does that controversial drug even work?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, Dorothy Pomerantz joins us to explain what it’s like to learn devastating medical information from the website of a consumer genetic testing company. Later, Amgen executive Dr. Greg Friberg joins us to explain why the company is betting on BiTEs, an approach to cancer immunotherapy that could succeed where CAR-Ts falter. Then, we dive into why Sarepta Therapeutics is yet to start an important clinical trial it promised the FDA three years ago.

You can listen to the episode here. To listen to future episodes, be sure to sign up on iTunes, Stitcher, Spotify, or wherever you get your podcasts.